COMPANY PROFILE

Egle Therapeutics

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically…

Paris, FranceFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Egle Therapeutics

Egle Therapeutics is a biotech startup that specializes in developing innovative immunotherapies. The company's primary focus is on targeting suppressor regulatory T cells (Tregs), which play a crucial role in the immune system. These cells are particularly relevant in the treatment of cancer and autoimmune diseases, where the immune response is often compromised.

Read full description

Founded in 2020, Egle Therapeutics was established by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, Director of the Translational Immunotherapy Team at Institut Curie. The company's approach combines the use of antibody-specific targeting with modified cytokine, a type of small protein important in cell signaling, to either enhance or suppress the most immunosuppressive Tregs. This unique method aims to restore the immune response, offering potential breakthroughs in the treatment of severe diseases.

Egle Therapeutics operates in the biotech market, serving clients in the medical and healthcare sectors. The company's business model is centered around the development and commercialization of its first-in-class immunotherapies. The company generates revenue through the development of its drug pipeline, which includes novel immunotherapies against Tregs.

The company's name, Egle, is inspired by the Greek myth of Aglaea, symbolizing beauty, splendor, glory, and magnificence. This reflects the company's mission to bring hope to patients suffering from severe diseases and to deploy remarkable science to meet unmet medical needs.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Paris, France
Employees: 52
Open positions: None listed
Dealroom signal: 80.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Woman Founder, participations bpifrance, radar de l'innovation, observatoire industrial tech, proteomics
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Mar 2025	$10M	—	France 2030	↗
SERIES AOther financing	Oct 2021	$44M	$176M	Takeda · FundPlus · Bioqube Ventures · Bpifrance	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Egle Therapeutics website traffic

Latest recorded traffic for Egle Therapeutics is 1.5K monthly website visits, down 50% over the last three months. Egle Therapeutics's team grew 6.1% over the past year.

Latest monthly visits1.5K 3-month web change-50% 1-year team growth+6.1%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AFAelis FarmaBiotech company conducting research and development on innovative signaling specific drugs	Bordeaux, France	Operational	27	$29M	$13M
IGIgyxosInnovative pharmaceutical products for human reproductive health	Nouzilly, France	Operational
EPENYO PharmaClinical stage biotech with an innovative approach inspired by viruses	Lyon, France	Operational
CTCoave TherapeuticsA clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases	Paris, France	Operational
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
TTThabor TherapeuticsA biotechnology company focused on treating human mucosal inflammatory diseases	Paris, France	Operational
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
INInnoSkelA pioneering biotechnology company developing therapies for rare skeletal diseases	Valbonne, France	Operational